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fusion genes promote tumor cell motility in
human osteosarcoma
Jilong Yang1,8*†, Matti Annala2,3†, Ping Ji4†, Guowen Wang1,8, Hong Zheng5,8, David Codgell4, Xiaoling Du9,
Zhiwei Fang7, Baocun Sun6,8, Matti Nykter2, Kexin Chen5,8* and Wei Zhang4*Abstract
Background: The identification of fusion genes such as SYT-SSX1/SSX2, PAX3-FOXO1, TPM3/TPM4-ALK and EWS-FLI1
in human sarcomas has provided important insight into the diagnosis and targeted therapy of sarcomas. No recurrent
fusion has been reported in human osteosarcoma.
Methods: Transcriptome sequencing was used to characterize the gene fusions and mutations in 11 human
osteosarcomas.
Results: Nine of 11 samples were found to harbor genetic inactivating alterations in the TP53 pathway. Two
recurrent fusion genes associated with the 12q locus, LRP1-SNRNP25 and KCNMB4-CCND3, were identified and
validated by RT-PCR, Sanger sequencing and fluorescence in situ hybridization, and were found to be osteosarcoma
specific in a validation cohort of 240 other sarcomas. Expression of LRP1-SNRNP25 fusion gene promoted SAOS-2
osteosarcoma cell migration and invasion. Expression of KCNMB4-CCND3 fusion gene promoted SAOS-2 cell migration.
Conclusions: Our study represents the first whole transcriptome analysis of untreated human osteosarcoma. Our
discovery of two osteosarcoma specific fusion genes associated with osteosarcoma cellular motility highlights the
heterogeneity of osteosarcoma and provides opportunities for new treatment modalities.
Keywords: Osteosarcoma, Transcriptome sequencing, Fusion gene, LRP1-SNRNP25, KCNMB4-CCND3Background
Among solid tumors, sarcomas were the first cancer
type associated with chromosomal translocations and
gene fusions [1]. Approximately 15–20% of sarcomas in
about 15 sarcoma types, including Ewing sarcoma, syn-
ovial sarcoma, desmoplastic small round cell tumor, alveo-
lar rhabdomyosarcoma, dermatofibrosarcoma protuberans
and myxoid liposarcoma have been found to harbor spe-
cific gene fusions [2-5]. The identification of fusion genes
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unless otherwise stated.ALK, BCOR-CCNB3 and EWS-FLI1 in human sarcomas
has provided important insight into the diagnosis and tar-
geted therapy of sarcomas [6-10]. However, no recurrent
fusion has ever been found in human osteosarcoma, al-
though osteosarcoma is known to exhibit frequent numer-
ical and structural chromosomal aberrations, such as
TP53 mutations and deletions, MDM2 amplification,
CDKN2A deletion, and hemi- or homozygous loss of RB1
[5,11,12].
A major challenge in the molecular study of osteosar-
coma is the difficulty of obtaining sufficient quantities of
fresh untreated tumor tissue, since neoadjuvant chemo-
therapy is often used prior to surgery in osteosarcoma.
Here we report the first transcriptome sequencing study
of untreated osteosarcoma. Two selectively rearranged
genomic loci that gave rise to fusion genes in 5 of 11 tu-
mors were detected. One hotspot in 17p associated with
TP53-disrupting rearrangements, while the other hotspotd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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fusion genes associated with the 12q locus, LRP1-
SNRNP25 and KCNMB4-CCND3, were validated and in-
vestigated. Our discovery of novel osteosarcoma fusion
genes and rearrangement hotspots provides important
insight into the role that chromosomal rearrangements
play in p53 pathway inactivation and regulation of cell
motility in osteosarcoma cells.
Results
Transcriptome sequencing cohort
Sarcoma tissue and information collection for this study
at Tianjin Medical University Cancer Institute & Hospital
(TMUCIH) was performed according to the protocol
approved by the Institutional Review Board (IRB) of
TMUCHIH and with patient consent. We acquired pri-
mary tumor tissue from 31 untreated osteosarcoma bi-
opsies obtained from the Tumor Tissue Bank (TTB) at
TMUCIH. A sufficient quantity of high quality RNA
was obtained from 11 of 31 cases (10 conventional sub-
type and 1 parosteal subtype). The cohort included 6
male and 5 female patients between 16 and 48 years of
age (Additional file 1: Table S1). Extracted whole RNA
was sequenced using IlluminaHiSeq™ 2000 instruments
at BGI. Sequence quality was high in all samples, with
30% of coding regions covered by 10× or higher cover-
age (Additional file 1: Figure S1). All Spearman correla-
tions between sample gene expression profiles were
above 0.85.
Identification of two fusion gene hotspots using
transcriptome sequencing
Fusion gene detection based on transcriptome sequen-
cing identified a total of 16 fusion genes in our cohort of
11 osteosarcomas. 7 of 11 osteosarcomas harbored at
least one fusion gene (Additional file 1: Figure S2, Tables
S1 and S2). We identified a pattern of interchromosomal
gene fusions clustered at two hotspots in the genome
(Figure 1). The first hotspot, rearranged in two osteosar-
comas (samples 1 and 6-2), coincided with the TP53
tumor suppressor gene in 17p. Sample 6-2 harbored a
fusion between TP53 and cyclinB1(CCNB1), while sample
1 had TP53 juxtaposed with the non-coding gene
AC016582.2, whose biological function is unknown. Both
fusions disrupted TP53 between exons 1 and 2, preventing
the production of p53 protein from one allele (Additional
file 1: Figure S3). Based on the fusion transcript structure,
neither TP53 rearrangement is expected to produce
chimeric protein.
The second hotspot, located in 12q, was rearranged in
four osteosarcomas (samples 1, 8, 9, 10) and coincided
with the genes MDM2 and CDK4 (Figure 1). MDM2
and CDK4 are known to be frequently co-amplified in
osteosarcoma and contribute to suppression of the p53and RB1 pathways (Figure 2A) [12-14]. A strong local-
ized gene dosage effect was observed in three of the four
12q-rearranged cases (samples 8, 9 and 10), suggesting
that fusion genes in this locus often arise as a by-
product of MDM2/CDK4 co-amplification (Figure 2B).
Many of the 12q fusion genes produced chimeric pro-
teins or disrupted cancer-associated genes such as
RUNX2, CCND3, and LRP1, indicating that some of the
fusions may contribute to cancer progression independ-
ently of MDM2/CDK4 co-amplification.
Widespread alteration of p53 and RB1 pathways in
osteosarcoma
Based on the observed rearrangements in the TP53 and
MDM2/CDK4 loci, we set out to analyze the p53 and RB1
pathways for further alterations. We used the transcrip-
tome sequencing data to look for oncogenic mutations in
expressed regions of the genome, and performed a gene
dosage analysis to identify signs of copy number alter-
ations. In addition to the two TP53-rearranged samples
(sample 1 and 6-2), we discovered a TP53 mutation
with loss-of-heterozygosity in one sample (sample 3-1)
(Figure 2C, Additional file 1: Figure S4), and TP53 dele-
tions in two samples (samples 2 and 6-1) (Figure 2C,
Additional file 1: Figure S5). Of the six remaining
osteosarcomas with intact TP53, three carried MDM2/
CDK4 co-amplification (samples 8, 9, and 10). Three sam-
ples had lost CDKN2A (samples 3-3, 4, and 10), and one
showed signs of RB1 loss (sample 11-2) (Figure 2C). Taken
together, all 11 osteosarcomas in our cohort had lost ei-
ther p53 or RB1 pathway function through one of these
mechanisms (Figure 2C).
Our mutation analysis revealed 522 non-synonymous
variants, including mutations in genes IDH1, IDH2,
SMARCB1, DNMT1, BRD7 and PIK3C3 (Figure 2C).
The IDH1 R132H mutation found in osteosarcoma
sample 3-1 is a frequent event in low-grade brain tu-
mors, central and periosteal chondromas, and central
chondrosarcomas [15,16]. Sample 3-1 also harbored a
non-synonymous mutation in SMARCB1, a gene that
has been associated with congenital risk of rhabdoid tu-
mors and chondrosarcomas [17]. Histopathological
analysis of neoplastic cells from sample 3-1 revealed
that they resided in lacunar spaces surrounded by hya-
line matrix and displayed a chondrocytic phenotype
with severe cytological atypia, confirming the diagnosis
of chondroblastic osteosarcoma.
Recurrent LRP1-SNRNP25 and KCNMB4-CCND3 fusion
genes in osteosarcoma
We selected the fusion genes LRP1-SNRNP25, KCNMB4-
CCND3, MDM2-RUNX2, TP53-CCNB1, DPM1-CD63
and ZFC3H1-MDM2 for further validation as they in-
volved genes known to be involved in cancer progression.
Figure 1 Transcriptome sequencing of 11 osteosarcomas revealed two hotspots of chromosomal rearrangement. One hotspot in 17p
was associated with TP53-disrupting rearrangements. The second hotspot in 12q was associated with MDM2/CDK4 co-amplification.
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sequencing cohort using RT-PCR and Sanger sequen-
cing targeted at fusion junctions (Figure 3A-C, Additional
file 1: Table S3, Figures S6–S11). We then used the same
RT-PCR assay on 20 additional osteosarcoma biopsies that
did not yield enough RNA for whole transcriptome se-
quencing (17 conventional, 2 parosteal, and 1 low gradeFigure 2 Recurrent TP53 pathway alterations in human osteosarcoma
RB1 pathways identified in our cohort. (B) Samples 8, 9, 10 harbored 12q
exclusive with alterations in the TP53 gene. (C) Matrix of genetic alteratio
alterations in the TP53 pathway genes.central subtype). Among the total 31 cases, only the
LRP1-SNRNP25 and KCNMB4-CCND3 fusion genes were
found to be recurrent, each found in 2 of 31 cases (6.5%)
(Figure 3B-C, Additional file 1: Figure S6). Matched nor-
mal white blood cells were negative for fusion transcripts,
demonstrating the somatic origin of the fusion genes
(Figure 3B, Additional file 1: Figure S6–S11).. (A) Activating (red) and inactivating (blue) alterations in the p53 and
co-amplification of CDK4 and MDM2. 12q amplification was mutually
ns observed in our cohort. Nine of 11 patients harbored disrupting
Figure 3 Validation and identification of fusion genes. (A) Structure of the LRP1-SNRNP25 fusion gene. Sanger sequencing of the fusion
junction is shown at the bottom. (B) RT-PCR validation of fusion transcript in the sequenced cohort. Matched normal white blood cells (WBC)
were negative for fusion. (C) RT-PCR identified a second fusion positive case in a validation cohort of 20 osteosarcomas. (D) Fusion leads to
elevated expression of SNRNP25 exons 2-5. (E) Interchromosomal rearrangement juxtaposing LRP1 and SNRNP25 was validated using fluorescence in
situ hybridization (FISH). Arrows indicate overlapping probes.
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KCNMB4-CCND3 fusions were specific to osteosarcomas,
we repeated our RT-PCR analysis on 240 fresh tissues
from 8 other sarcoma subtypes, including 56 malignant fi-
brous histiocytoma/undifferentiated pleomorphic sarcoma(MFH/UPS), 50 liposarcomas, 24 soft tissue leiomyosarco-
mas, 4 rhabdomyosarcomas, 21 synovial sarcomas, 13
chondrosarcoma, 8 EWS/PNETs, and 64 malignant per-
ipheral nerve sheath tumors (MPNSTs) (Additional file 1:
Table S4). None of the 240 other sarcomas was positive
Yang et al. Journal of Hematology & Oncology 2014, 7:76 Page 5 of 10
http://www.jhoonline.org/content/7/1/76for LRP1-SNRNP25 or KCNMB4-CCND3 fusions, nor for
the four other fusion genes found in our analysis.
In both LRP1-SNRNP25 positive tumors, the fusion
juxtaposed exon 8 of LRP1 with exon 2 of SNRNP25
(Figure 3A) and resulted in increased expression of
SNRNP25 under control of the LRP1 promoter (Figure 3D).
The fusion was in-frame and produced a chimeric protein
that merged the first 409 amino acids of LRP1’s extra-
cellular domain with the ubiquitin-like domain (amino
acids 24-132) of SNRNP25.
Since LRP1 and SNRNP25 are normally located on
different chromosomes, we set out to validate the inter-
chromosomal rearrangement using FISH. We used bac-
terial artificial chromosome (BAC) probes to label the
two genes in frozen sections from the two positive
cases. More than 90% cells displayed LRP1 probes,
SNRNP25 probes and the overlapping probes, validating
the rearrangement (Figure 3E). The FISH also revealed
amplification of both LRP1 and SNRNP25, suggesting a
complex genetic alteration of osteosarcoma. Similar
FISH assays validated the KCNMB4-CCND3 rearrange-
ment (Additional file 1: Figure S6D).
In the KCNMB4-CCND3 positive cases, the fusion jux-
taposed exon 1 of KCNMB4 with exon 4 of CCND3
(Additional file 1: Figure S6). The fusion was in-frame
and produced a chimeric protein that merged the cyto-
plasmic and transmembrane domains (112 amino acids)
of KCNMB4 with amino acids 67-292 of CCND3. Most
sarcoma-associated fusion genes such as SYT-SSX1/SSX2,
BCOR-CCNB3, EWS-FLI1, PAX3-FOXO1 and COL1A1-
PDGFB produce functional proteins [6-9,18]. We sought
to detect chimeric KCNMB4-CCND3 and LRP1-SNRNP25
protein products in 31 human osteosarcoma tissues by
western blotting with antibodies against CCND3,
KCNMB4, SNRNP25 and LRP1. Unfortunately our
antibodies detected no evidence of fusion proteins in
either the RT-PCR positive or negative cases. To in-
vestigate chimeric protein products in tissue sections,
we analyzed protein expression of LRP1, SNRNP25,
KCNMB4 and CCND3 in 4 fusion positive and 27 fu-
sion negative osteosarcomas with the same antibodies,
but found no significant difference in protein expres-
sion between fusion positive and negative cases.LRP1-SNRNP25 and KCNMB4-CCND3 contribute to tumor
cell motility
To study any oncogenic contribution conferred by fu-
sion genes in our cohort, we cloned the LRP1-
SNRNP25 and KCNMB4-CCND3 fusion genes into
pcDNA3.1 expression vectors and validated the vec-
tors by sequencing (Additional file 1: Figure S12A).
Transfection of the LRP1-SNRNP25 and KCNMB4-
CCND3 fusion genes into human osteosarcomaSAOS-2 cells resulted in detectable expression of fu-
sion proteins (Additional file 1: Figure S12B).
Since LRP1 and CCND3 play important roles in regu-
lating tumor cell migration, invasion, proliferation and
apoptosis in other cancers [19-22], we set out to test
whether the chimeric proteins might play any role in
osteosarcoma cells. A cell transformation assay with
Rat2 fibroblast cells revealed that neither fusion was suffi-
cient to transform Rat2 fibroblast cells (Additional file 1:
Figure S12C) or to augment K-Ras V12 driven cell
transformation (Additional file 1: Figure S12D). In soft
agar colony formation assays, neither fusion promoted
anchorage-independent colony formation relative to
GFP controls (Additional file 1: Figure S12E). Prolifera-
tion of SAOS-2 cells was inhibited rather than in-
creased after fusion transfection (Additional file 1:
Figure S12F). However, both the LRP1-SNRNP25 and
KCNMB4-CCND3 fusions significantly promoted cell mi-
gration of SAOS-2 cells in transwell assays (Figure 4A),
and LRP1-SNRNP25 also promoted invasion significantly
(Figure 4B). A wound healing assay corroborated these
findings, showing that both fusions accelerated cell migra-
tion (Figure 4C). Clinically, both LRP1-SNRNP25 positive
patients had tumor recurrence 21 months after surgery,
and one of the patients developed lung metastases after
6 months. One of the KCNMB4-CCND3 positive patients
also had his tumor recur 6 months after surgery.
Discussion
Osteosarcoma is the most common histological form of
primary bone sarcoma and predominantly inflicts chil-
dren and young adults. While it is often characterized as
a genomically unstable bone sarcoma, no recurrent gene
translocation and fusion genes has ever been reported in
human osteosarcoma, except for one report which re-
vealed exon 6 of the cAMP-responsive element binding
protein 3-like 1 gene (CREB3L1) fused in-frame to the
EWSR1 exon 11 in a case of small cell osteosarcoma
[23].The most important discovery of the present study
is the detection of two recurrent fusion genes, LRP1-
SNRNP25 and KCNMB4-CCND3, which are validated by
RT-PCR, Sanger sequencing and FISH. Furthermore,
preliminary functional studies show that expression of
LRP1-SNRNP25 and KCNMB4-CCND3 fusion genes
promotes SAOS-2 osteosarcoma cell migration, while
LRP1-SNRNP25 expression also promotes invasion.
Taken together, these data suggest that LRP1-SNRNP25
and KCNMB4-CCND3 fusions confer an oncogenic ef-
fect in human osteosarcoma by enhancing cancer cell
motility.
Further investigation into the functional roles of
KCNMB4-CCND3 and LRP1-SNRNP25 is necessary, par-
ticularly to investigate the mechanisms through which
the fusion genes affect invasion/migration. LRP1 encodes
Figure 4 LRP1-SNRNP25 and KCNMB4-CCND3 fusion genes promoted human osteosarcoma SAOS-2 cells motility relative to empty
vector. (A) Transwell migration assay. Both the LRP1-SNRNP25 and KCNMB4-CCND3 fusions significantly promoted cell migration of SAOS-2 cells.
(B) Transwell invasion assay. While the LRP1-SNRNP25 promoted invasion of SAOS-2 cells significantly, KCNMB4-CCND3 fusions did not significantly
promote cell invasion. (C) Wound healing assay showed that both fusions accelerated the osteosarcoma cell migration.
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tumor cell invasion, migration, proliferation, and apop-
tosis [24,25]. LRP1 forms a signaling complex with
PDGFR-beta in endosomes and regulates activation ofthe MAPK pathway [24]. Furthermore, LRP1 promotes
anti-apoptotic signaling in neurons by activating the
AKT survival pathway [25]. In healthy cells, cyclin D3
(CCND3) regulates the G1/S cell cycle transition by
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kinases 4 and 6 (CDK4/CDK6). Regulated by HDAC5,
miR-195, miR-138, and miR-16 family, CCND3 triggers
an accumulation of cells in S phase [19-22]. In GIST and
glioblastoma, CCND3 has been shown to be a key target
of miR-195-induced inhibition of cell invasion [19-22].
Thus, the mechanisms through which these two
KCNMB4-CCND3 and LRP1-SNRNP25 fusion genes
may affect invasion/migration appear to be complex.
Our preliminary data shows that the MMP-2, MMP-9,
p-AKT, pERK, pMAPK, and JNK were increased sig-
nificantly in transfected SAOS-2 tumor cells, while
caspase-3 and Ki-67 did not change significantly (data
not shown). These results suggest that the fusion
events might promote tumor cell invasion and migra-
tion by elevating MMPs and activating the AKT and
MAPK signaling pathways. Future studies will be
needed to shed light on the driving mechanisms.
The recurrent fusion genes LRP1-SNRNP25 and
KCNMB4-CCND3 found in this study both involved a
5′ partner gene located near the MDM2/CDK4 locus in
12q. This suggests that the fusion genes arise as a by-
product of the chromosomal rearrangements that result
in MDM2/CDK4 co-amplification. However, the recurrent
nature of these fusions suggests that they are selected for
during osteosarcoma development. This hypothesis is sup-
ported by the observation that all four LRP1-SNRNP25
and KCNMB4-CCND3 fusions had a transcript structure
compatible with production of chimeric protein. Fusion
genes that arise as a by-product of somatic copy number
alterations but contribute an independent oncogenic effect
have been observed in other cancers. In glioblastoma,
EGFR-SEPT14 and EGFR-PSPH fusions associated with
EGFR amplification were recently observed to result in
constitutive activation of EGFR signaling [26,27].
One limitation of the current study is the limited cohort
size of 31 osteosarcomas. We hope to move forward by
collaborating with other cancer centers and research
groups that possess more untreated or treated osteosar-
coma samples. Another limitation is that we did not iden-
tify the genomic breakpoints and protein products
associated with KCNMB4-CCND3 and LRP1-SNRNP25
fusions in clinical samples. In the future we will perform
whole genome sequencing of the fusion gene positive
cases to define the exact genetic breakpoints. Another
limitation is the fact that the fusion are low frequency
events. This may reflect the high genetic heterogeneity of
osteosarcomas.
Conclusion
The present study represents the first whole transcriptome
sequencing study of untreated human osteosarcoma. Our
discovery of two osteosarcoma specific fusion genes asso-
ciated with cell motility may provide opportunities fornew treatment modalities. The findings of our study sup-
port the view that the majority of osteosarcomas harbor
alterations in the p53 pathway, including recurrent trans-
locations disrupting the TP53 gene. Future studies with an
expanded cohort will determine how frequent these
events are and whether these gene fusions can potentially
serve as therapeutic targets in future clinical practice.Material and methods
Samples and RNA extraction and quality control
Sarcoma tissue and information collection for this study
at Tianjin Medical University Cancer Institute & Hospital
(TMUCIH) was performed according to the protocol
approved by the Institutional Review Board (IRB) of
TMUCHIH and with patient consent. We obtained 31
untreated osteosarcoma tissues from the Tumor Tissue
Bank (TTB) at TMUCIH. All samples had at least 90%
tumor content. Tumors were snap frozen in liquid ni-
trogen. After crushing tumors, we isolated total RNA
using the TRIzol reagent kit (Invitrogen) that employs a
method based on GITC-phenol-chloroform extraction.
RNA was quantified with Qubit (Invitrogen) and Nanodrop
ND1000 (ThermoFisher Scientific) before quality as-
sessment with the Agilent 2100 Bioanalyzer. For blood
white cell RNA isolation, we used the same method. Ex-
tracted whole RNA was sequenced using IlluminaHiSeq™
2000 at the Beijing Genomics Institute (BGI).RNA library construction
PolyA mRNA was purified from 10 μg of total RNA using
NucleoTrap mRNA (Macherey Nagel) according to the
manufacturer’s protocol. Following the IlluminaHiSeq™
2000 total RNA Seq kit instructions, we fragmented
100 ng of poly-A RNA by incubation with RNAse III for
10 min in a 10 μl reaction volume containing 1× RNAse
III buffer with the enzyme. Fragmented RNA was then
purified using the RiboMinus Concentration Module
(Invitrogen). The yield and size distribution of the frag-
mented RNA was assessed using the Quant-iT RNA assay
kit with the Qubitfluorometer (Invitrogen) and the RNA
6000 Pico Chip kit with the Agilent 2100 Bioanalyzer. A
total of 50 ng of fragmented RNA was hybridized and li-
gated with the SOLiD adaptor mix and reverse transcribed
according to the manufacturer’s instructions.
The isolated cDNA was size selected to be ~200 bp
using Novex pre-cast gel products. The cDNA was then
amplified according to the IlluminaHiSeq™ 2000 Total
RNA Seq kit protocol. The yield and size distribution
of the cDNA were assessed using the Quant-iT HS
DNA assay kit with the Qubitfluorometer and the High
Sensitivity DNA Assay Chip kit on the Agilent 2100
Bioanalyzer.
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Beads with oligo(dT) were used to isolate poly(A) mRNA
after total RNA was collected. Fragmentation buffer was
used to cleave mRNA into short fragments. Taking these
short fragments as templates, random hexamer primers
were used to synthesize the first-strand cDNA. Second-
strand cDNA was synthesized using buffer, dNTPs, RNase
H and DNA polymerase I. Short fragments were purified
with QiaQuick PCR extraction kit and resolved with EB
buffer for end reparation and poly(A) addition. The short
fragments were then ligated with sequencing adaptors.
Agarose gel electrophoresis was used to select fragments
suitable for amplification with PCR. The templated beads
from each sample were deposited on two quadrants of a
slide. Massively parallel ligation sequencing was carried
out using IlluminaHiSeq™ 2000 instruments at the Beijing
Genomics Institute following the manufacturer’s instruc-
tions. Each sequencing run produced approximately 50
million paired end reads where each mate was 90 bp in
length.Gene and exon expression analysis
Whole transcriptome sequencing reads were aligned
against the GRCh37 human reference genome using
Tophat version 2.0.4 [28]. The number of overlapping
reads was calculated for all exons and then for all genes
annotated in Ensembl 67. Gene expression values were
normalized across samples using median-of-ratios
normalization. In this normalization method, expression
profiles are normalized by calculating an expression ratio
between two samples for every gene (or exon), and then
taking the median of those ratios. All gene expression
values are then multiplied by the median-of-ratios. Only
genes covered by 500 or more total reads were used in
calculating the median-of-ratios.Fusion gene detection
To achieve robust results, fusion gene discovery was per-
formed using two different strategies [29]. In the first
strategy, we applied the ChimeraScan fusion gene detec-
tion software by Iyer et al. to the raw FASTQ format se-
quencing data [30]. ChimeraScan used Bowtie 0.12.8 for
read alignment [31]. Anchor length was set to 25 bp.
One nucleotide mismatch was allowed in the initial
alignments and in the alignment of discordant reads. Fu-
sion gene candidates with less than 20 spanning reads
were filtered out in order to focus the analysis on
strongly expressed fusion genes.
The second strategy was to use an unpublished in-
house fusion detection algorithm called Breakfast to val-
idate the ChimeraScan results and to search for fusiongenes where the fusion junction did not occur on an
exon-exon junction, but instead disrupted an exon. The
Breakfast algorithm operates on aligned SAM files, and
therefore we first aligned whole transcriptome sequen-
cing reads against the GRCh37 human reference genome
using Tophat version 2.0.4 [28]. Breakfast searched the
alignment data for discordant read pairs and unaligned
individual mates. For discordant read pairs, we required
the mates to be at least one megabase apart. The align-
ment quality of both mates in a discordant pair was re-
quired to be above 15 (phred). Next, individual unaligned
mates were split into two 25 bp anchors that were ex-
tracted from both ends of each 90 bp mate. The 25 bp an-
chors were then re-aligned against the GRCh37 human
reference genome using Bowtie 0.12.8 [31], and the result-
ing alignments were searched for evidence of discordantly
aligned anchor pairs. Breakfast then constructs clusters of
evidence for chromosomal rearrangements using both dis-
cordant read pairs and anchor pairs. To achieve this, the
discordant read pairs were reoriented to be in forward-
forward orientation. To produce the final list of rearrange-
ment candidates, we filtered out any rearrangements that
were not supported by at least 1 paired read and 3 anchor
pairs, or by at least 10 anchor pairs.RT-PCR and sanger sequencing
Fusion genes were validated using RT-PCR amplification
of fusion gene breakpoints of chimeric cDNA and Sanger
sequencing. The PCR reactions were 10 min at 95°C;
30 cycles of 30 sec at 95°C, 30 sec at 58–62°C and 30 sec
at 72°C and finally 10 min at 72°C. Complementary to the
RNA quality control in the RNA-seq and to control the
RT-PCR system, primers of β-actin gene were also de-
signed to amplify β-actin simultaneously with fusion gene
RT-PCR.Fluorescence in situ hybridization of fusion genes
We obtained fluorescence labeled bacterial artificial
chromosome (BAC) probes for LRP1, SNRNP25,
KCNMB4 and CCND3(Empire Genomics) for FISH
analysis on frozen sections from the two fusion posi-
tive cases [32]. Orange-5TAMRA-dUTP labeled BAC
clone RP11-110 J7 was used to identify the LRP1 gene
and green-5TAMRA-dUTP labeled BAC clone CTD-3077
J14 was used to identify the SNRNP25 gene. For fusion
KCNMB4-CCND3 gene, orange-5TAMRA-dUTP labeled
BAC clone RP11-626E3 was used to identify the KCNMB4
gene and green-5TAMRA-dUTP labeled BAC clone
RP11-720D9 was used to identify the CCND3 gene. Be-
cause the genes are located on different chromosomes,
overlap of green and orange signals in tumor nucleus indi-
cates gene fusion.
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The detection of possible fusion proteins in osteosar-
coma tissue lysate and FFPE tissue sections by western
blotting and immunohistochemistry used anti-CCND3,
anti-KCNMB4, anti-LRP-1 antibodies (ab28283, ab89703
and ab92544, ABCAM, Cambridge, MA) and anti-
SNRNP25 antibody (H00079622-B01, Novus, Littleton,
CO).Fusion cDNA cloning, cell transformation, stable human
osteosarcoma cell transfection, tumor cell proliferation,
invasion, migration, and mobility
The cDNA from fusion genes positive cases was PCR
amplified with Phusion DNA polymerase (Finnzymes,
Fisher Scientific) and EcoRV_LRP1_fw and XhoI_
SNRNP25_rev primers. The EcoRV-Xho1 digested
fragment was then ligated into a pcDNA3.1(+) vector
(Invitrogen) between EcoRV and XhoI restriction sites.
The complete cDNA sequences were verified. KCNMB4-
CCND3 was cloned in similar fashion.
Rat2 cells were seeded into a 6-well plate one day be-
fore transfection. Solution A contained 50 μl OPTI-
MEM medium and 2 μg plasmid DNA with fusion genes
or GFP or Ras V12G control vector. Solution B contained
of 50 μl OPTI-MEM medium and 5 μl lipofectamine 2000
(Invitrogin). Solutions A and B were mixed and the mix-
ture was kept for 20 min at room temperature, then added
to a well containing Rat2 cells in 400 μl OPTI-MEM
medium. Transfected Rat2 cells were cultured in regular
cell culture conditions with the medium replaced twice a
week. The foci were fixed with 3.7% formaldehyde solu-
tion for 10 minutes and stained with crystal violet solution
for 1 hour and washed with water overnight.
The human osteosarcoma cell line SAOS-2 was ob-
tained from ATCC and maintained in Eagle’s minimum
essential medium supplemented with 10% fetal bovine
serum and 1% penicillin-streptomycin solution. Cells
were incubated at 37°C in a humidified atmosphere of 5%
CO2. LRP1-SNRNP25 and KCNMB4-CCND3 constructs
were transfected into SAOS-2 cells by lipofectamine 2000
and selected stable cells with 600 μg/ml G418 for 2 weeks.
Fusion gene expression was validated by western blotting
with anti-CCND3and anti-SNRNP25 antibodies.
Six-well plate with 0.5% agar in medium as the bottom
layer was used for soft agar colony formation assay. For
each well, 2.5 × 103 cells suspended in medium with
0.375% agarose were plated as top layer and incubated at
37°C for 3 weeks. Three sets were used for each sample.
Colonies were stained with 0.005% Crystal violet and
counted.
Tumor cell proliferation assay by BrdU incorporation
and cell invasion and migration assays by transwell assay
were performed as previously described [29].Additional file
Additional file 1: The clinical information of 11 human osteosarcoma
patients and the results of osteosarcoma transcriptome sequencing
data, including the fusion gene list, fusion gene structures, fusion
gene validations by PR-PCR, p53 mutations, fusion gene transfection
and functional studies.
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